Cargando…

Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions

PURPOSE: Prostatic lesions on routine staining sometimes cause a diagnostic dilemma, especially when malignant tissue is limited and is mixed with benign prostatic glands or because of the presence of benign mimickers of carcinoma. The application of immunohistochemistry contributes a valuable diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Monika, Kaur, Gurmeen, Malhotra, Vineeta, Garg, Ravish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society (APPS) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879051/
https://www.ncbi.nlm.nih.gov/pubmed/24392438
http://dx.doi.org/10.12954/PI.13026
_version_ 1782297910405234688
author Garg, Monika
Kaur, Gurmeen
Malhotra, Vineeta
Garg, Ravish
author_facet Garg, Monika
Kaur, Gurmeen
Malhotra, Vineeta
Garg, Ravish
author_sort Garg, Monika
collection PubMed
description PURPOSE: Prostatic lesions on routine staining sometimes cause a diagnostic dilemma, especially when malignant tissue is limited and is mixed with benign prostatic glands or because of the presence of benign mimickers of carcinoma. The application of immunohistochemistry contributes a valuable differential diagnosis. This study aimed to evaluate a complete spectrum of various prostatic lesions and to supplement the histopathological diagnosis with immunohistochemistry in suspicious or atypical cases. METHODS: A total of 364 consecutive prostatic specimens were evaluated. Routine hematoxylin and eosin staining and immunohistochemical staining against 34βE12 cytokeratin and proliferative marker (alpha-methylacyl-CoA-racemase, AMACR) were performed by use of the peroxidase antiperoxidase method. RESULTS: Benign prostatic hyperplasia was the most frequent finding and involved 285 patients (78.3%). Prostatitis (majority nonspecific) formed the predominant subgroup in nonneoplastic lesions (n=119, 32.7%). The incidence of carcinoma was low (n=73, 20.1%). Of the 26 atypical or suspicious cases, 18 cases were positive for high molecular weight cytokeratin (high molecular weight cytokeratin, HMWCK) only, 4 cases were positive for AMACR only, and 4 cases showed positivity for both HMWCK and AMACR. CONCLUSIONS: Biopsy remains the gold standard. However, as an adjunct to biopsy, proliferative markers and basal cell markers have value for resolving suspicious or atypical cases.
format Online
Article
Text
id pubmed-3879051
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Asian Pacific Prostate Society (APPS)
record_format MEDLINE/PubMed
spelling pubmed-38790512014-01-03 Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions Garg, Monika Kaur, Gurmeen Malhotra, Vineeta Garg, Ravish Prostate Int Original Articles PURPOSE: Prostatic lesions on routine staining sometimes cause a diagnostic dilemma, especially when malignant tissue is limited and is mixed with benign prostatic glands or because of the presence of benign mimickers of carcinoma. The application of immunohistochemistry contributes a valuable differential diagnosis. This study aimed to evaluate a complete spectrum of various prostatic lesions and to supplement the histopathological diagnosis with immunohistochemistry in suspicious or atypical cases. METHODS: A total of 364 consecutive prostatic specimens were evaluated. Routine hematoxylin and eosin staining and immunohistochemical staining against 34βE12 cytokeratin and proliferative marker (alpha-methylacyl-CoA-racemase, AMACR) were performed by use of the peroxidase antiperoxidase method. RESULTS: Benign prostatic hyperplasia was the most frequent finding and involved 285 patients (78.3%). Prostatitis (majority nonspecific) formed the predominant subgroup in nonneoplastic lesions (n=119, 32.7%). The incidence of carcinoma was low (n=73, 20.1%). Of the 26 atypical or suspicious cases, 18 cases were positive for high molecular weight cytokeratin (high molecular weight cytokeratin, HMWCK) only, 4 cases were positive for AMACR only, and 4 cases showed positivity for both HMWCK and AMACR. CONCLUSIONS: Biopsy remains the gold standard. However, as an adjunct to biopsy, proliferative markers and basal cell markers have value for resolving suspicious or atypical cases. Asian Pacific Prostate Society (APPS) 2013 2013-12-30 /pmc/articles/PMC3879051/ /pubmed/24392438 http://dx.doi.org/10.12954/PI.13026 Text en Copyright © 2013 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Garg, Monika
Kaur, Gurmeen
Malhotra, Vineeta
Garg, Ravish
Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions
title Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions
title_full Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions
title_fullStr Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions
title_full_unstemmed Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions
title_short Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions
title_sort histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879051/
https://www.ncbi.nlm.nih.gov/pubmed/24392438
http://dx.doi.org/10.12954/PI.13026
work_keys_str_mv AT gargmonika histopathologicalspectrumof364prostaticspecimensincludingimmunohistochemistrywithspecialreferencetogreyzonelesions
AT kaurgurmeen histopathologicalspectrumof364prostaticspecimensincludingimmunohistochemistrywithspecialreferencetogreyzonelesions
AT malhotravineeta histopathologicalspectrumof364prostaticspecimensincludingimmunohistochemistrywithspecialreferencetogreyzonelesions
AT gargravish histopathologicalspectrumof364prostaticspecimensincludingimmunohistochemistrywithspecialreferencetogreyzonelesions